At a glance
ClinicalIndex Comparison RecordN/ACompleted· 55 enrolled
Drug / intervention
Balafilcon A contact lenses (PureVision) +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of Deposits on Contact Lenses Worn Daily Wear
In Brief
A clinical study evaluating Balafilcon A contact lenses (PureVision) and Etafilcon A contact lenses (Acuvue2) for Refractive Error. Completed, enrolled 55 participants across 1 site.
Detailed Summary
The purpose of this study was to measure front surface deposits on contact lenses when worn for ten hours.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRefractive Error
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2008
First PostedJul 2008
Primary CompletionSep 2008
TodayJul 2026
First PostedJul 30, 2008
Enrollment StartMar 1, 2008
Primary CompletionSep 1, 2008
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 17.9 years ago
Interventions
Balafilcon A contact lenses (PureVision)device
Commercially marketed, soft contact lenses worn bilaterally for 10 hours
Etafilcon A contact lenses (Acuvue2)device
Commercially marketed, soft contact lenses worn bilaterally for 10 hours